StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
11
Publishing Date
2024 - 03 - 04
14
2023 - 12 - 21
13
2023 - 12 - 12
13
2023 - 12 - 06
14
2023 - 11 - 27
13
2023 - 10 - 23
12
2023 - 10 - 18
13
2023 - 10 - 16
16
2023 - 10 - 04
14
2023 - 09 - 26
18
2023 - 09 - 20
12
2023 - 09 - 07
15
2023 - 08 - 23
12
2023 - 06 - 26
13
2023 - 06 - 15
12
2023 - 04 - 27
12
2023 - 04 - 25
15
2023 - 04 - 17
15
2023 - 03 - 27
12
2023 - 02 - 23
13
2023 - 01 - 30
16
2023 - 01 - 26
12
2023 - 01 - 25
15
2023 - 01 - 04
12
2022 - 11 - 17
13
2022 - 10 - 12
14
2022 - 10 - 06
14
2022 - 09 - 14
14
2022 - 09 - 13
12
2022 - 08 - 22
13
2022 - 05 - 24
12
2022 - 05 - 17
13
2022 - 05 - 03
14
2022 - 03 - 28
14
2022 - 01 - 24
18
2021 - 12 - 22
12
2021 - 12 - 13
15
2021 - 12 - 09
12
2021 - 12 - 06
13
2021 - 11 - 01
12
2021 - 10 - 18
15
2021 - 10 - 14
12
2021 - 10 - 12
12
2021 - 10 - 07
12
2021 - 10 - 04
12
2021 - 09 - 07
12
2021 - 06 - 29
12
2021 - 06 - 25
13
2021 - 06 - 23
14
2021 - 06 - 21
13
2021 - 06 - 11
11
2021 - 06 - 04
13
2021 - 06 - 03
12
2021 - 06 - 01
14
2021 - 05 - 21
15
2021 - 05 - 03
14
2021 - 04 - 14
11
2021 - 03 - 22
13
2021 - 01 - 04
11
2020 - 12 - 21
12
Sector
Health technology
8
Manufacturing
1
Producer manufacturing
1
Professional, scientific, and technical services
1
Tags
Application
3
Atopic dermatitis
1
Biomarkers
1
Biopharma
1
Biotechnology
2
Clearance
2
Clinical-trials-phase-ii
1
Clinical-trials-phase-iii
1
Conference
2
Covid
3
Cystic fibrosis
1
Dermatitis
1
Designation
2
Disease
1
Drug
1
Education
1
Efruxifermin
1
Ema
1
Enroll
1
Fast track
1
Fast track designation
1
Fda
3
Fda clearance
2
Fda fast track
1
Fda-approvals
1
Fibrosis
1
Genetown
1
Lenzilumab
1
N/a
4
Nash
1
New drug
1
News
1
Phase 1
1
Phase 1b
1
Phase 2
1
Phase 2b
1
Presentation
1
Research
2
Treatment
11
Trial
3
Vaccine
1
Entities
Akero therapeutics, inc.
1
Chart industries, inc.
1
Cyclo therapeutics inc - class a
1
Enanta pharmaceuticals, inc.
1
First wave biopharma, inc.
1
Humanigen, inc.
1
Johnson & johnson
1
Moleculin biotech, inc.
1
Plus therapeutics, inc.
1
Vertex pharmaceuticals incorporated
1
Vyne therapeutics inc.
1
Symbols
AKRO
1
CYTH
1
ENTA
1
FWBI
1
GTLS
1
HGEN
1
JNJ
1
MBRX
1
PSTV
1
VRTX
1
VYNE
1
Exchanges
Nasdaq
10
Nyse
1
Crawled Date
2021 - 10 - 19
11
Crawled Time
11:00
1
12:00
3
13:00
3
15:00
2
17:00
1
21:00
1
Source
www.biospace.com
7
www.globenewswire.com
2
www.prnewswire.com
1
www.vynetherapeutics.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
treatment
publishing date :
2021 - 10 - 19
save search
Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH
Published:
2021-10-19
(Crawled : 21:00)
- biospace.com/
AKRO
|
$20.585
0.37%
200K
|
Health Technology
|
-4.43%
|
O:
-4.61%
H:
5.52%
C:
4.79%
treatment
fda
fda fast track
fast track
nash
efruxifermin
fast track designation
designation
Covid News Brief: Vaccine Boosters, Profits, Treatment Updates and More
Published:
2021-10-19
(Crawled : 17:00)
- biospace.com/
JNJ
|
News
|
$147.17
0.98%
3.2M
|
Health Technology
|
-9.47%
|
O:
0.49%
H:
2.64%
C:
1.85%
covid
treatment
vaccine
Cyclo Therapeutics Recognizes Niemann-Pick Disease Awareness Month Highlighting Need for Broader Awareness and Support for Research to Find a Treatment
Published:
2021-10-19
(Crawled : 15:00)
- biospace.com/
CYTH
|
$1.15
-4.17%
25K
|
Professional, Scientific, and T...
|
-81.74%
|
O:
-0.13%
H:
3.78%
C:
0.44%
disease
treatment
ema
research
First Wave BioPharma Announces FDA Clearance of IND Application for Phase 2a PASSPORT Trial of FW-ICI-AC as Treatment for Immune Checkpoint Inhibitor-Associated Colitis
Published:
2021-10-19
(Crawled : 15:00)
- biospace.com/
FWBI
|
$2.59
-8.8%
69K
|
Manufacturing
|
4.03%
|
O:
6.23%
H:
1.38%
C:
-3.1%
fda clearance
treatment
fda
phase 2
biopharma
application
trial
clearance
phase 2b
Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
Published:
2021-10-19
(Crawled : 13:00)
- prnewswire.com
MBRX
|
News
|
$4.5235
2.9K
|
Health Technology
|
68.66%
|
O:
0.37%
H:
3.72%
C:
2.23%
covid
treatment
phase 1
trial
phase 1b
VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
Published:
2021-10-19
(Crawled : 13:00)
- vynetherapeutics.com
VYNE
|
$2.29
-0.43%
11K
|
Health Technology
|
101.75%
|
O:
-0.88%
H:
4.42%
C:
-1.77%
treatment
atopic dermatitis
dermatitis
trial
enroll
Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
Published:
2021-10-19
(Crawled : 13:00)
- biospace.com/
VRTX
|
News
|
$395.0
0.39%
550K
|
Health Technology
|
118.45%
|
O:
0.7%
H:
1.94%
C:
1.84%
treatment
fibrosis
conference
cystic fibrosis
Enanta Pharmaceuticals Presents New Data for EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19, at the ISIRV–WHO Virtual Conference 2021
Published:
2021-10-19
(Crawled : 12:00)
- biospace.com/
ENTA
|
$12.79
-3.33%
51K
|
Health Technology
|
-78.6%
|
O:
0.31%
H:
1.44%
C:
1.17%
covid
treatment
conference
designation
Plus Therapeutics Announces FDA Clearance of Investigational New Drug Application for 186RNL for the Treatment of Leptomeningeal Metastases
Published:
2021-10-19
(Crawled : 12:00)
- globenewswire.com
PSTV
|
$1.67
-1.27%
4.6K
|
Health Technology
|
-1.17%
|
O:
4.68%
H:
0.0%
C:
-1.96%
new drug
fda clearance
treatment
fda
application
drug
clearance
Humanigen Announces Late-Breaking Presentation at the CHEST Annual Meeting Highlighting C-Reactive Protein as a Biomarker for Identifying Patients Most Likely to Benefit from treatment with Lenzilumab
Published:
2021-10-19
(Crawled : 12:00)
- biospace.com/
HGEN
|
$0.0361
-61.5%
120M
|
Health Technology
|
-99.42%
|
O:
0.16%
H:
4.62%
C:
4.46%
presentation
treatment
lenzilumab
biomarkers
ChartWater™ backs researchers developing new treatment processes and applications at IHE Delft Institute for Water Education
Published:
2021-10-19
(Crawled : 11:00)
- globenewswire.com
GTLS
|
$148.3
-0.18%
130K
|
Producer Manufacturing
|
-18.77%
|
O:
0.26%
H:
1.76%
C:
0.05%
education
treatment
application
research
Gainers vs Losers
72%
28%
Top 10 Gainers
AGBA
|
News
|
$1.27
217.5%
120M
|
Finance
EGOX
|
$0.054
50.0%
290M
|
RWOD
|
$10.52
31.56%
5.9M
|
n/a
ZCMD
|
$1.905
31.38%
30M
|
Commercial Services
NVFY
|
$2.71
28.44%
31M
|
Consumer Durables
MRDB
4
|
$0.536
27.65%
2M
|
n/a
BSFC
|
$0.0822
27.64%
75M
|
Manufacturing
TPET
|
$0.4121
25.68%
45M
|
n/a
INDO
|
$5.1
25.0%
15M
|
Energy Minerals
CHRO
|
$1.53
24.9%
100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.